Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
At week 68, the mean weight reduction in the CagriSema group was 13.7%, compared with 3.4% in the placebo group, yielding a significant between-group difference of 10.4% (95% CI: 11.29.5
Administration Route: Subcutaneous or intramuscular injection, consistent with published clinical and preclinical research protocols
Repeat with Second mL Clean the water vial top again, draw another 1 mL, and inject the same way
no large-scale, placebo-controlled human trial has confirmed efficacy comparable to licensed treatments such as minoxidil or finasteride
"FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize." 2025
US$ 28.55
US$ 29.96
US$ 22.60
US$ 24.64
US$ 20.58
